\
&
Contact us
\
&
Contact us
A deep dive into specific issues and answers to commonly asked questions. This section is regularly updated
What exactly is a cascade call? What can you expect from these calls?
This infosheet on international cooperation provides an overview of all types of countries for Horizon Europe participation and its eligibilty.
This infosheet provides an overview of the timeline towards the next EU Framework Programme for research & innovation as well as an overview of position and discussion papers that have been published so far.
Certain calls for proposals require the submission of Ownership Control Declarations as mandatory annex to the application.
European Digital Infrastructure Consortia (EDICs) are a new instrument to implement Multi-Country Projects to achieve the objectives of Europe's Digital Decade.
The Commission takes ethics seriously and expect every consortium to self-reflect, but they equally invest in screenings and follow-up. Next to the medical field, ethical issues typically emerge in environmental, social science or security research.
Lump sum funding is gradually introduced in several EU funding programmes with the aim to reduce administration and financial errors. Lump sums grants have a budget defined at proposal stage and fixed in the grant agreement.
All basic information you need to find out whether EDF is something for you and how to get started in EDF
An overview of projects that have been selected for funding
The EU Defence Innovation Scheme (EUDIS) is a set of instruments enabled by the European Defence Fund (EDF) to strengthen defence innovation in the European Union.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
